{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:03:03Z","timestamp":1795089783770,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>WAP four-disulfide core domain 2 (WFDC2) is a small secretory protein that has been widely studied in ovarian cancer. It has been proven that WFDC2 promotes proliferation and metastasis in ovarian cancer, and serves as a diagnostic biomarker. However, the specific function of WFDC2 in prostate cancer has not been reported. Here, we first screened the diagnostic marker and favorable prognostic factor WFDC2 in prostate cancer by bioinformatics. WFDC2 expression was negatively correlated with Gleason score and metastasis in prostate cancer. Then, we revealed that overexpression of WFDC2, and addition of recombinant protein HE4 can significantly inhibit prostate cancer metastasis in vivo and in vitro. By co-immunoprecipitation and co-localization assays, we proved that WFDC2 binds to the extracellular domain of epidermal growth factor receptor (EGFR). Immunoblot showed that WFDC2 overexpression and recombinant protein HE4 addition inactivated the EGFR\/AKT\/GSK3B\/Snail signaling pathway, and then restrained the progression of epithelial\u2013mesenchymal transition. In conclusion, our study identified that the tumor suppressor WFDC2 can suppress prostate cancer metastasis by inactivating EGFR signaling.<\/jats:p>","DOI":"10.1038\/s41419-020-02752-y","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T06:02:53Z","timestamp":1594879373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation"],"prefix":"10.1038","volume":"11","author":[{"given":"Yaoyi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lushun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-3628","authenticated-orcid":false,"given":"Lingao","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1377-9685","authenticated-orcid":false,"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-0024","authenticated-orcid":false,"given":"Xinghuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"2752_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.canlet.2019.01.035","volume":"448","author":"K Nikhil","year":"2019","unstructured":"Nikhil, K. et al. Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer. Cancer Lett. 448, 182\u2013196 (2019).","journal-title":"Cancer Lett."},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2017.03.009","volume":"44","author":"K Rycaj","year":"2017","unstructured":"Rycaj, K., Li, H., Zhou, J., Chen, X. & Tang, D. G. Cellular determinants and microenvironmental regulation of prostate cancer metastasis. Semin. Cancer Biol. 44, 83\u201397 (2017).","journal-title":"Semin. Cancer Biol."},{"key":"2752_CR4","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/0008-5472.CAN-16-1536","volume":"77","author":"S Tohme","year":"2017","unstructured":"Tohme, S., Simmons, R. L. & Tsung, A. Surgery for cancer: a trigger for metastases. Cancer Res. 77, 1548\u20131552 (2017).","journal-title":"Cancer Res."},{"key":"2752_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nature19465","volume":"536","author":"CR Alarcon","year":"2016","unstructured":"Alarcon, C. R. & Tavazoie, S. F. Cancer: endothelial-cell killing promotes metastasis. Nature 536, 154\u2013155 (2016).","journal-title":"Nature"},{"key":"2752_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs, A. M. et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat. Cell Biol. 19, 518\u2013529 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2752_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.canlet.2014.09.021","volume":"356","author":"R Qureshi","year":"2015","unstructured":"Qureshi, R., Arora, H. & Rizvi, M. A. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett. 356, 321\u2013331 (2015).","journal-title":"Cancer Lett."},{"key":"2752_CR8","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.3390\/ijms14036026","volume":"14","author":"J Li","year":"2013","unstructured":"Li, J. et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int. J. Mol. Sci. 14, 6026\u20136043 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"2752_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2017.08.020","volume":"147","author":"BA Goff","year":"2017","unstructured":"Goff, B. A. et al. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol. Oncol. 147, 291\u2013295 (2017).","journal-title":"Gynecol. Oncol."},{"key":"2752_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-243","volume":"13","author":"H Zhuang","year":"2014","unstructured":"Zhuang, H. et al. Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol. Cancer 13, 243 (2014).","journal-title":"Mol. Cancer"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fonc.2017.00332","volume":"7","author":"JR Ribeiro","year":"2017","unstructured":"Ribeiro, J. R. et al. Human Epididymis protein 4 promotes events associated with metastatic ovarian cancer via regulation of the extracelluar matrix. Front. Oncol. 7, 332 (2017).","journal-title":"Front. Oncol."},{"key":"2752_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.18632\/oncotarget.6327","volume":"7","author":"L Zhu","year":"2016","unstructured":"Zhu, L. et al. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget 7, 729\u2013744 (2016).","journal-title":"Oncotarget"},{"key":"2752_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).","journal-title":"BMC Bioinformatics"},{"key":"2752_CR14","first-page":"2168","volume":"41","author":"B Liu","year":"2019","unstructured":"Liu, B. et al. Analysis of gene coexpression network reveals prognostic significance of CNFN in patients with head and neck cancer. Oncol. Rep. 41, 2168\u20132180 (2019).","journal-title":"Oncol. Rep."},{"key":"2752_CR15","doi-asserted-by":"crossref","unstructured":"Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 (2017).","DOI":"10.1126\/science.aan2507"},{"key":"2752_CR16","first-page":"189","volume":"30","author":"J Mariategui","year":"1967","unstructured":"Mariategui, J., Chavez, H. & Oballe, J. [About a new anticonvulsant psychotropic. Preliminary results with carbamazepine]. Rev. Neuropsiquiatr. 30, 189\u2013197 (1967).","journal-title":"Rev. Neuropsiquiatr."},{"key":"2752_CR17","doi-asserted-by":"crossref","unstructured":"Sachs, M. C. plotROC: a tool for plotting ROC curves. J. Stat. Softw. 79, 1\u201319 (2017).","DOI":"10.18637\/jss.v079.c02"},{"key":"2752_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"2752_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"2752_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"2752_CR22","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1038\/528S117a","volume":"528","author":"H Brody","year":"2015","unstructured":"Brody, H. Prostate cancer. Nature 528, S117 (2015).","journal-title":"Nature"},{"key":"2752_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2017.11.038","volume":"73","author":"J Luo","year":"2018","unstructured":"Luo, J. et al. Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting. Eur. Urol. 73, 715\u2013723 (2018).","journal-title":"Eur. Urol."},{"key":"2752_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467\u2013479 (2014).","journal-title":"Eur. Urol."},{"key":"2752_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","volume":"71","author":"M Del Re","year":"2017","unstructured":"Del Re, M. et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol. 71, 680\u2013687 (2017).","journal-title":"Eur. Urol."},{"key":"2752_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L. & Engelman, J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282\u2013303 (2014).","journal-title":"Cancer Cell"},{"key":"2752_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ccell.2018.02.012","volume":"33","author":"YN Wang","year":"2018","unstructured":"Wang, Y. N. et al. Angiogenin\/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer. Cancer Cell 33, 752\u2013769 (2018).","journal-title":"Cancer Cell"},{"key":"2752_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2017.09.017","volume":"171","author":"DM Freed","year":"2017","unstructured":"Freed, D. M. et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171, 683\u2013695 (2017).","journal-title":"Cell"},{"key":"2752_CR29","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1074\/jbc.M413919200","volume":"280","author":"BS Kochupurakkal","year":"2005","unstructured":"Kochupurakkal, B. S. et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J. Biol. Chem. 280, 8503\u20138512 (2005).","journal-title":"J. Biol. Chem."},{"key":"2752_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","volume":"110","author":"TP Garrett","year":"2002","unstructured":"Garrett, T. P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110, 763\u2013773 (2002).","journal-title":"Cell"},{"key":"2752_CR31","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","volume":"16","author":"CS Tan","year":"2015","unstructured":"Tan, C. S., Gilligan, D. & Pacey, S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 16, e447\u2013e459 (2015).","journal-title":"Lancet Oncol."},{"key":"2752_CR32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960\u20131966 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2752_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123\u2013132 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2752_CR34","doi-asserted-by":"crossref","unstructured":"Zhangyuan, G. et al. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway. Oncogene 39, 1213\u20131230 (2020).","DOI":"10.1038\/s41388-019-1052-7"},{"key":"2752_CR35","doi-asserted-by":"crossref","unstructured":"Williams, C. B. et al. HUNK phosphorylates EGFR to regulate breast cancer metastasis. Oncogene 39, 1112\u20131124 (2020).","DOI":"10.1038\/s41388-019-1046-5"},{"key":"2752_CR36","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.7150\/thno.31716","volume":"9","author":"F Du","year":"2019","unstructured":"Du, F. et al. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR. Theranostics 9, 3879\u20133902 (2019).","journal-title":"Theranostics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02752-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02752-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:42:43Z","timestamp":1760085763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-02752-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-02752-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"8 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"537"}}